Using targeted therapies alone for rheumatoid arthritis

Joint Bone Spine

Volumn 78, Issue 1, 2011, Pages 1-3

  Prati, Clément ^a   Wendling, Daniel ^a  

^a UNIVERSITÉ DE FRANCHE COMTÉ   (France)

Author keywords

Biologic agents; Rheumatoid arthritis; Treatment

Indexed keywords

ABATACEPT; ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6; METHOTREXATE; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADD ON THERAPY; B LYMPHOCYTE; BLOOD TOXICITY; CELL POPULATION; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HUMAN; IMMUNIZATION; LIVER TOXICITY; MONOTHERAPY; NONHUMAN; REGISTER; RHEUMATOID ARTHRITIS; RISK FACTOR; T LYMPHOCYTE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL THERAPY; HUMANS;

EID: 78651065370     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2010.10.003     Document Type: Editorial

References (21)

1. Maini R., St Clair E.W., Breedveld F., et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999, 354:1932-1939.
2. Bijlsma J.W., Jacobs J.W. Methotrexate: still the anchor drug in RA treatment. Joint Bone Spine 2009, 76:452-454.
3. Saag K.G., Teng G.G., Patkar N.M., et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008, 59:762-784.
4. Hyrich K.L., Watson K.D., Silman A.J., et al. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2006, 45:1558-1565.
5. Hyrich K.L., Symmons D.P., Watson K.D., et al. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006, 54:1786-1794.
6. Gottenberg J.E., Ravaud P., Bardin T., et al. Prospective follow-up of rituximab treatment in 1407 patients with refractory rheumatoid arthritis (1175 patients/years): tolerance and efficacy data from the French AIR (AutoImmunity and Rituximab) registry. Ann Rheum Dis 2009, 68(Suppl. 3):442. [Abstract FRI0258].
7. Gottenberg J.E., Ravaud P., Bardin T., et al. Tolérance et efficacité du traitement de l'abatacept chez 682 patients atteints de polyarthrite rhumatoïde (353 patients/année): données prospectives du registre Orencia and Rheumatoid Arthritis (ORA). Rev Rhum 2009, 76:980. [(Abstract)PO 7].
8. Maini R.N., Breedveld F.C., Kalden J.R., et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998, 41:1552-1563.
9. Genovese M.C., Bathon J.M., Martin R.W., et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002, 46:1443-1450.
10. Klareskog L., van der Heijde D., de Jager J.P., et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004, 363:675-681.
11. van der Heijde D., Klareskog L., Rodriguez-Valverde V., et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 2006, 54:1063-1074.
12. van Riel P.L., Taggart A.J., Sany J., et al. Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study. Ann Rheum Dis 2006, 65:1478-1483.
13. Breedveld F.C., Weisman M.H., Kavanaugh A.F., et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006, 54:26-37.
14. van de Putte L.B., Atkins C., Malaise M., et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004, 63:508-516.
15. Edwards J.C., Szczepanski L., Szechinski J., et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004, 350:2572-2581.
16. Moreland L.W., Alten R., Van den Bosch F., et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 2002, 46:1470-1479.
17. Jones G., Sebba A., Gu J., et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010, 69:88-96.
18. Nishimoto N., Miyasaka N., Yamamoto K., et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol 2009, 19:12-19.
19. Nishimoto N., Hashimoto J., Miyasaka N., et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X-ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007, 66:1162-1167.
20. Bresnihan B., Alvaro-Gracia J.M., Cobby M., et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998, 41:2196-2204.
21. Ward M., Liang M.H., Burns T., et al. RA treatment: improvement in RA management. Joint Bone Spine 2009, 76:435-437.